Expression and Clinical Significance of MSI2 in Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YANGZi-guo ,  GUOXiao-bo , SHIYu-long , LIChen-sheng , LILe-ping

Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China;

Corresponding author：

GUOXiao-bo, Email: xiaoboguo@hotmail.com

Keywords：

Gastric cancer; MSI2; Clinical factor; Invasion; Prognosis

DOI：

10.7507/1007-9424.20160014

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the expression of MSI2 in gastric cancer and its association with clinical significance. Methods The expression level of MSI2 mRNA in gastric cancer tissues and para-carcinoma tissues was detected by Real-time PCR to explore its clinical significance. The expression level of MSI2 protein was detected by Western blotting. The prognosis of patients with the ratio of MSI2 mRNA expression level in gastric cancer tissues and adjacent normal tissues was more than 2 times and below 2 times were compared. Results There was no significant difference between the expressions of MSI2 mRNA in cancer tissues and para-carcinoma tissues(P > 0.05). The expression level of MSI2 mRNA were associated with the invasion depth (P=0.017), TNM stage (P=0.028), differentiation (P=0.020), and size (P=0.030) of tumor, but no association with other clinical factors such as gender, age, and location were found. The overall survival of the patients with high expression of MSI2 mRNA was significantly shorter than that of the patients with low expression of MSI2 mRNA (χ²=4.221, P=0.040). Conclusion MSI2 expression is associated with the gastric cancer invasion, TNM stage and differentiation, and the patients with higher expression of MSI2 mRNA have poor prognosis, which makes it possible to be a potential therapeutic target.

Citation： YANGZi-guo, GUOXiao-bo, SHIYu-long, LIChen-sheng, LILe-ping. Expression and Clinical Significance of MSI2 in Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(1): 52-55. doi: 10.7507/1007-9424.20160014 Copy

1.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
2.	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5):E359-E386.
3.	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
4.	Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol, 2006, 12(1):17-20.
5.	de Andres-Aguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis. Curr Opin Hematol, 2012, 19(4):268-272.
6.	Glazer RI, Wang XY, Yuan H, et al. Musashi1:a stem cell marker no longer in search of a function. Cell Cycle, 2008, 7(17):2635-2639.
7.	Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med, 2010, 16(8):903-908.
8.	Park SM, Gonen M, Vu L, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest, 2015, 125(3):1286-1298.
9.	Mu Q, Wang Y, Chen B, et al. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia. Leuk Res, 2013, 37(8):922-927.
10.	Okano H, Kawahara H, Toriya M, et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res, 2005, 306(2):349-356.
11.	Toda M, Iizuka Y, Yu W, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia, 2001, 34(1):1-7.
12.	高志刚, 郭克建, 宋少伟. MSI2在胰腺癌中的表达及其临床意义.中华胰腺病杂志, 2014, 14(6):392-395.
13.	何璐, 周新科, 洪健.肝细胞癌中Musashi2的表达及意义.广东医学, 2013, 34(20):3152-3154.
14.	Aly RM, Ghazy HF. Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia. Int J Lab Hematol, 2015, 37(2):272-278.
15.	Kaeda J, Ringel F, Oberender C, et al. Up-regulated MSI2 is associ-ated with more aggressive chronic myeloid leukemia. Leuk Lymphoma, 2015, 56(7):2105-2113.
16.	Han Y, Ye A, Zhang Y, et al. Musashi-2 silencing exerts potent acti-vity against acute myeloid leukemia and enhances chemosensitivity to daunorubicin. PLoS One, 2015, 10(8):e0136484.
17.	Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun, 2015, 6:6517.
18.	王娅菲, 林中, 卢青, 等. musashi-2、CD133在结肠腺癌中的表达.天津医药, 2013, 41(12):1153-1155.
19.	Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells:promise of targeted therapy. Gastroenterology, 2010, 138(6):2151-2162.
20.	莫碧文, 李劳冬, 于会娜, 等. Musashi2在肺癌中的表达及其临床意义.安徽医科大学学报, 2013, 48(12):1480-1483.
21.	Moreira AL, Gonen M, Rekhtman N, et al. Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol, 2010, 23(6):889-895.
22.	MacNicol AM, Wilczynska A, MacNicol MC. Function and regula-tion of the mammalian Musashi mRNA translational regulator. Biochem Soc Trans, 2008, 36(Pt 3):528-530.
23.	He L, Zhou X, Qu C, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med, 2014, 18(1):49-58.
24.	Wang MH, Qin SY, Zhang SG, et al. Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/beta-catenin pathway. Am J Cancer Res, 2015, 5(3):1089-1100.
25.	Cox JL, Wilder PJ, Gilmore JM, et al. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One, 2013, 8(5):e62857.
26.	Emadi-Baygi M, Nikpour P, Mohammad-Hashem F, et al. MSI2 expression is decreased in gradeⅡof gastric carcinoma. Pathol Res Pract, 2013, 209(11):689-691.

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5):E359-E386.
3. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
4. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol, 2006, 12(1):17-20.
5. de Andres-Aguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis. Curr Opin Hematol, 2012, 19(4):268-272.
6. Glazer RI, Wang XY, Yuan H, et al. Musashi1:a stem cell marker no longer in search of a function. Cell Cycle, 2008, 7(17):2635-2639.
7. Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med, 2010, 16(8):903-908.
8. Park SM, Gonen M, Vu L, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest, 2015, 125(3):1286-1298.
9. Mu Q, Wang Y, Chen B, et al. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia. Leuk Res, 2013, 37(8):922-927.
10. Okano H, Kawahara H, Toriya M, et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res, 2005, 306(2):349-356.
11. Toda M, Iizuka Y, Yu W, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia, 2001, 34(1):1-7.
12. 高志刚, 郭克建, 宋少伟. MSI2在胰腺癌中的表达及其临床意义.中华胰腺病杂志, 2014, 14(6):392-395.
13. 何璐, 周新科, 洪健.肝细胞癌中Musashi2的表达及意义.广东医学, 2013, 34(20):3152-3154.
14. Aly RM, Ghazy HF. Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia. Int J Lab Hematol, 2015, 37(2):272-278.
15. Kaeda J, Ringel F, Oberender C, et al. Up-regulated MSI2 is associ-ated with more aggressive chronic myeloid leukemia. Leuk Lymphoma, 2015, 56(7):2105-2113.
16. Han Y, Ye A, Zhang Y, et al. Musashi-2 silencing exerts potent acti-vity against acute myeloid leukemia and enhances chemosensitivity to daunorubicin. PLoS One, 2015, 10(8):e0136484.
17. Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun, 2015, 6:6517.
18. 王娅菲, 林中, 卢青, 等. musashi-2、CD133在结肠腺癌中的表达.天津医药, 2013, 41(12):1153-1155.
19. Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells:promise of targeted therapy. Gastroenterology, 2010, 138(6):2151-2162.
20. 莫碧文, 李劳冬, 于会娜, 等. Musashi2在肺癌中的表达及其临床意义.安徽医科大学学报, 2013, 48(12):1480-1483.
21. Moreira AL, Gonen M, Rekhtman N, et al. Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol, 2010, 23(6):889-895.
22. MacNicol AM, Wilczynska A, MacNicol MC. Function and regula-tion of the mammalian Musashi mRNA translational regulator. Biochem Soc Trans, 2008, 36(Pt 3):528-530.
23. He L, Zhou X, Qu C, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med, 2014, 18(1):49-58.
24. Wang MH, Qin SY, Zhang SG, et al. Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/beta-catenin pathway. Am J Cancer Res, 2015, 5(3):1089-1100.
25. Cox JL, Wilder PJ, Gilmore JM, et al. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One, 2013, 8(5):e62857.
26. Emadi-Baygi M, Nikpour P, Mohammad-Hashem F, et al. MSI2 expression is decreased in gradeⅡof gastric carcinoma. Pathol Res Pract, 2013, 209(11):689-691.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression and Clinical Significance of MSI2 in Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content